New Aspects of Cancer Stem Cell Biology

New Aspects of Cancer Stem Cell Biology

Stem Cell

The cancer stem cell (CSC) paradigm represents one of the most prominent breakthroughs of the last decades in tumor biology. CSCs are that subpopulation within a tumor that can survive conventional therapies and as a consequence are able to fuel tumor recurrence. Nevertheless, the biological characteristics of CSCs and even their existence, remain the main topic among tumor biologists debates. The difficulty in achieving a better definition of CSC biology may actually be explained by the plasticity of such a cell subpopulation. Indeed, the emerging view is that CSCs represent a dynamic “state” of tumor cells that can acquire stemness-related properties under specific circumstances, rather than referring to a well-defined group of cells. Regardless of their origin, it is clear that designing novel antitumor treatments based on the eradication of CSCs will only be possible upon unraveling the biological mechanisms that underlie their pathogenic role in tumor progression and therapy resistance. The Special Issue on “New aspects of cancer stem cell biology: implications for innovative therapies” aims at highlighting recent insights into CSC features that can make them an attractive target for novel therapeutic strategies.
URI
https://directory.doabooks.org/handle/20.500.12854/69328
Keywords
Cadherin 11; WNT signaling; β-catenin; cancer stem cells; TNBC; early breast cancer; bevacizumab; neoadjuvant chemotherapy; ALDH1; solid cancer; chemo-resistance; HDAC inhibitors; head and neck squamous cell carcinoma; SRC; dasatinib; saracatinib; EC-8042; Ovarian cancer; Wnt signaling; tumor progression; therapy resistance; exosomes; oral cancer risk; oral epithelial dysplasia; SOX2; immunohistochemistry; oral squamous cell carcinoma; genome-wide; transcriptome; lung cancer; ATAC-seq; RNA-seq; CSCs; NSCLC; B4GALT1; LUAD; breast cancer; lipid; metabolism; therapeutic resistance; bowel cancer; organoid; tumoroid; colorectal; colon; stem cell; chemotherapy resistance; ovarian cancer; cancer stem cell; genetic heterogeneity; SNP array; L1CAM; chemoresistance; epithelial-mesenchymal transition; cancer therapy; cell adhesion molecule

Cavallaro, Ugo (editor)

Giordano, Marco (editor)

https://directory.doabooks.org/handle/20.500.12854/69328

MDPI - Multidisciplinary Digital Publishing Institute

2020

Dewi Puspitasari

https://creativecommons.org/licenses/by/4.0/

Burrell, R.A.; Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol.
2014, 8, 1095–1111. [CrossRef] [PubMed]

Pdf

English

Textbooks

DOI
10.3390/books978-3-03943-407-7

ISBN
9783039434060, 9783039434077

Basel